| Revenue growth | 13% YoY growth driven by 11% volume and 2% ARPP increase. |
|---|---|
| Margins | Margins improved to 19.4% from 18.2% YoY via non-institutional mix. |
| Demand visibility | Sustained demand for oncology services; 16/25 centers hit record quarterly revenue. |
| Management confidence | High; emphasizing resilience of oncology model and strategic capacity expansion. |
Growth
Revenue hit INR 6,951 Mn with 11% volume growth. Adjusted EBITDA margins expanded 120bps to 19.4% due to higher non-institutional business.
Outlook
Commissioned 120+ bed North Bangalore hospital; added 121 operational beds across network this quarter.
Risks
Adjusted PAT fell 59.6% QoQ. New North Bangalore hospital currently operating at a loss of INR 70 Mn.
Last quarter's promises, checked
Delivered
- Guided 15%+ revenue growth → delivered 13% (Close to target/BEAT on EBITDA)
- Guided 10% volume growth → delivered 11% (= BEAT)
- Guided Q4 launch for North Bangalore → Delivered May 2026 (= BEAT)
Partly delivered
- Guided EBITDA margin expansion (18.5% YTD) → delivered 19.4% (= BEAT on absolute, PARTIAL on trajectory vs 23-24% goal)
Missed
- Guided 5% ARPP growth → delivered 2% (= MISS)
Earnings Call Transcript filed with BSE, NSE: HCG. Summary written with AI assistance from the document.
Healthcare Global Enterprises Ltd: key numbers
- Share price
- ₹698.65
- Market cap
- ₹10,431 Cr
- Revenue (annual)
- ₹2,545 Cr
- Net profit (annual)
- ₹13.76 Cr
- P/E (TTM)
- 457.5×Sector 57.8×
- Promoter holding
- 64.21%+0.00% QoQ
- FII holding
- 2.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Healthcare Global Enterprises Ltd
All →Healthcare Global Enterprises Annual General Meeting
HealthCare Global Enterprises held its 28th Annual General Meeting on September 18, 2026, via video conferencing to transact business items listed in the notice.
Healthcare Global Enterprises Employee Stock Options
HealthCare Global Enterprises Limited granted 64,46,843 employee stock options under its ESOS 2026 scheme. The grant carries an exercise price of INR 495 per share.
Healthcare Global Enterprises Investor Presentation: Key Takeaways
HCG reported strong Q1 FY27 results with 13% YoY revenue growth and 20% Adjusted EBITDA growth. Strategic focus on oncology and capacity expansion through a new North Bengaluru facility.
Healthcare Global Enterprises Q1 FY27 Results: Net Profit ₹16.5 Cr, Up 175.0% YoY
Healthcare Global Enterprises Ltd reported revenue from operations of ₹693.4 Cr (+13.3% YoY) and net profit of ₹16.5 Cr (+175.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹16.5 Cr · +175.0% YoY
Healthcare Global Enterprises Earnings Call: Key Takeaways
HCG delivered strong FY26 performance with 15% revenue growth and margin expansion. Strategy focuses on oncology core through the sale of fertility unit Milann and brownfield expansion.
Healthcare Global Enterprises Earnings Call: Key Takeaways
HCG delivered strong FY26 results with 15% revenue growth and margin expansion to 18.5%, driven by operational leverage and clinical excellence.